Chugai Pharmaceutical Co., Ltd. (CUP0.MU)
- Previous Close
24.60 - Open
25.00 - Bid 25.20 x --
- Ask 25.60 x --
- Day's Range
25.00 - 25.00 - 52 Week Range
13.90 - 25.60 - Volume
0 - Avg. Volume
0 - Market Cap (intraday)
83.793B - Beta (5Y Monthly) 0.70
- PE Ratio (TTM)
32.47 - EPS (TTM)
0.77 - Earnings Date Jul 24, 2025
- Forward Dividend & Yield 0.30 (1.18%)
- Ex-Dividend Date Jan 2, 2025
- 1y Target Est
--
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Perjeta, Polivy, Tecentriq, and Phesgo; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept for immunosuppressant; Edirol, an osteoporosis agent; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi for spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Ronapreve, an anti-SARS-CoV-2 monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company has strategic alliances and collaboration with Roche Group; and research collaboration and option to license agreement with Araris Biotech AG to develop ADCs using Araris AraLinQ technology. The company was founded in 1925 and is headquartered in Chuo-ku, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.
www.chugai-pharm.co.jp5,026
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: CUP0.MU
View MorePerformance Overview: CUP0.MU
Trailing total returns as of 5/1/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CUP0.MU
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CUP0.MU
View MoreValuation Measures
Market Cap
83.44B
Enterprise Value
77.61B
Trailing P/E
32.52
Forward P/E
29.41
PEG Ratio (5yr expected)
5.50
Price/Sales (ttm)
10.91
Price/Book (mrq)
6.99
Enterprise Value/Revenue
10.29
Enterprise Value/EBITDA
21.74
Financial Highlights
Profitability and Income Statement
Profit Margin
33.56%
Return on Assets (ttm)
17.92%
Return on Equity (ttm)
23.11%
Revenue (ttm)
1.22T
Net Income Avi to Common (ttm)
410.15B
Diluted EPS (ttm)
0.77
Balance Sheet and Cash Flow
Total Cash (mrq)
944.55B
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
286.45B